Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
June 06, 2023 06:00 ET
|
ZENTALIS PHARMACEUTICALS
ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing schedule; New RP2D...
Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting
May 25, 2023 17:38 ET
|
ZENTALIS PHARMACEUTICALS
Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4 months in combination with paclitaxel, and a confirmed ORR of 35.7%...
Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations
May 23, 2023 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Overview of data to be presented at the 2023 ASCO Annual Meeting to be included in the update Live webcast to be held on Tuesday, June 6th at 8:00 a.m. ET NEW YORK and SAN DIEGO, May 23, 2023 ...
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
May 10, 2023 07:00 ET
|
ZENTALIS PHARMACEUTICALS
On track to disclose monotherapy dose and updates on currently accruing trials for azenosertib, a potentially first-in-class and best-in-class WEE1 inhibitor, in 1H 2023 Positive Phase 1b azenosertib...
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting
April 26, 2023 10:00 ET
|
ZENTALIS PHARMACEUTICALS
Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for...
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
April 17, 2023 09:00 ET
|
ZENTALIS PHARMACEUTICALS
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company anticipates sharing clinical data from ovarian chemotherapy...
Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates
March 01, 2023 07:00 ET
|
ZENTALIS PHARMACEUTICALS
On track to declare monotherapy RP2D for potentially first-in-class/best-in-class Wee1 inhibitor, azenosertib (ZN-c3), and provide program updates and potential paths to registration in 1H 2023 ...
Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer
February 13, 2023 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2023 17:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
February 01, 2023 07:01 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically...